Ethanesulfonyl-piperidine derivatives

US6310213A · kind A · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Alexander Alanine · Basel, CH
• Serge Burner · Mulhouse, FR
• Bernd Buttelmann · Schopfheim, DE
• Marie-Paule Heitz Neidhart · Rixheim, FR
• Georg Jaeschke · Basel, CH
• Emmanuel Pinard · Rixheim, FR
• Rene Wyler · Zürich, CH

Key dates

• Filing date: Jun 2, 2000
• Grant date: Oct 30, 2001
• Expiry date: Jun 2, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D211/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to compounds of the general formula ##STR1## wherein PA1 R.sup.1 signifies hydrogen or hydroxy; R.sup.2 signifies hydrogen or methyl; and X signifies --O-- or --CH.sub.2 -- and their pharmaceutically acceptable acid addition salts. It has been shown that these compounds have a good affitity to the NMDA receptor and they are therefore useful in the treatment of diseases, wherein the therapeutic indications include acute forms of neurodegeneration caused, e.g., by stroke or brain trauma; chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease or ALS (amyotrophic lateral sclerosis); neurodegeneration associated with bacterial or viral infections, and, diseases such as schizophrenia, anxiety, depression and chronic/acute pain.